Literature DB >> 15505987

Serum prostate-specific antigen concentration is increased in acromegalic women.

L Manetti1, I Lupi, M Genovesi, L Morselli, L Grasso, C Nencetti, M Gasperi, F Bogazzi, L Bartalena, E Martino.   

Abstract

Prostate-specific antigen (PSA) is a serine proteases produced by prostatic epithelial cells detectable in male serum and seminal plasma. PSA is also expressed in some female tissues and fluids and is increased in hirsute women showing a positive correlation with androgens. Accordingly, it has been suggested that PSA might be a marker of androgen action in women. The aim of this observational study was to assess serum PSA concentration in acro megalic women with active disease, in remission or during somatostatin analogs therapy. Forty-four acromegalic women, 15 with active disease, 10 in remission and 19 under long-acting somatostatin analogs therapy were enrolled in the study; 273 normal women matched for age, body mass index, with no signs of hirsutism, served as controls. Serum PSA, 3a-androstanediol (3alpha-AG), total testosterone (T), DHEAS, LH, FSH and estradiol were assessed. No patient or control had been given estrogen or antiandrogen drugs; no acromegalic women had hyperprolactinemia or hypopituitarism. Serum PSA concentration was significantly higher in acromegalic patients than in control subjects (p < 0.0001). Patients with active acromegaly or under somatostatin analogs therapy had significant higher serum PSA concentration than controls, while patients in remission after adenomectomy did not differ. Serum PSA was detectable in serum of 75% acromegalic women and 45% of controls. In addition 24% of acromegalic women had serum PSA concentrations higher than the mean +/- 2SD of control subjects. Differences in serum PSA levels did not reach statistical significance in the different acromegalic subgroups possibly because of the small number of subjects, but patients with active acromegaly had higher serum PSA levels than patients under somatostatin analogs therapy or in remission. Acromegalic women had significantly higher serum PSA concentrations than controls both before and after menopause (p < 0.01). 3alpha-AG (p < 0.05) and T (p < 0.01) were higher in acromegalic than in control subjects in pre-menopause (PM) but not in post-menopause (M). A correlation was found in the whole group of acromegalic patients between serum PSA and 3a-AG concentrations (r = 0.3, p < 0.01). In conclusion, acromegalic is associated with an increase in serum PSA concentrations as a group, although this increase is observed, at an individual level, in only 24% of cases. Patients whose disease is controlled by somatostatin analogs or has been cured by pituitary adenomectomy tend to have lower serum PSA levels than patients with active disease. M patients tend to have lower PSA values than PM women, consistent with the main androgen control of PSA production. However, the observation that M women still have higher serum PSA levels than controls suggest that in acromegaly PSA is regulated not only by androgens but also by the GH/IGF-I system itself.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15505987     DOI: 10.1007/BF03347496

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  27 in total

1.  Antiandrogen drugs lower serum prostate-specific antigen (PSA) levels in hirsute subjects: evidence that serum PSA is a marker of androgen action in women.

Authors:  C Negri; F Tosi; R Dorizzi; A Fortunato; G G Spiazzi; M Muggeo; R Castello; P Moghetti
Journal:  J Clin Endocrinol Metab       Date:  2000-01       Impact factor: 5.958

2.  A prostate antigen in sera of prostatic cancer patients.

Authors:  L D Papsidero; M C Wang; L A Valenzuela; G P Murphy; T M Chu
Journal:  Cancer Res       Date:  1980-07       Impact factor: 12.701

3.  Prostate-specific antigen in female serum, a potential new marker of androgen excess.

Authors:  D N Melegos; H Yu; M Ashok; C Wang; F Stanczyk; E P Diamandis
Journal:  J Clin Endocrinol Metab       Date:  1997-03       Impact factor: 5.958

Review 4.  Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis.

Authors:  A Dunaif
Journal:  Endocr Rev       Date:  1997-12       Impact factor: 19.871

5.  Nonprostatic sources of prostate-specific antigen.

Authors:  E P Diamandis; H Yu
Journal:  Urol Clin North Am       Date:  1997-05       Impact factor: 2.241

6.  The 'female prostate': location, morphology, immunohistochemical characteristics and significance.

Authors:  N Wernert; M Albrech; I Sesterhenn; R Goebbels; H Bonkhoff; G Seitz; R Inniger; K Remberger
Journal:  Eur Urol       Date:  1992       Impact factor: 20.096

7.  Human androgen receptor binding to the androgen response element of prostate specific antigen.

Authors:  M C Luke; D S Coffey
Journal:  J Androl       Date:  1994 Jan-Feb

Review 8.  Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era.

Authors:  R T McCormack; H G Rittenhouse; J A Finlay; R L Sokoloff; T J Wang; R L Wolfert; H Lilja; J E Oesterling
Journal:  Urology       Date:  1995-05       Impact factor: 2.649

9.  Prostate-specific antigen is increased in female patients with Cushing's disease.

Authors:  L Manetti; I Lupi; F Bogazzi; G Pellegrini; A Precisi; L Grasso; C Nencetti; M Gasperi; E Martino
Journal:  J Endocrinol Invest       Date:  2002-10       Impact factor: 4.256

10.  Proteolysis of insulin-like growth factor-binding protein-3 in the male reproductive tract.

Authors:  S R Plymate; C J Rosen; C A Paulsen; J L Ware; J Chen; R E Vessella; R S Birnbaum
Journal:  J Clin Endocrinol Metab       Date:  1996-02       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.